Ligand-Binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: Strategic approach and application to peptibodies targeting the thrombopoietin receptor

AAPS Journal

Volumn 12, Issue 4, 2010, Pages 576-585

  Hall, Michael P ^a   Gegg, Colin ^a   Walker, Kenneth ^a   Spahr, Christopher ^a   Ortiz, Robert ^a   Patel, Vimal ^a   Yu, Steven ^a   Zhang, Liana ^a   Lu, Hsieng ^a   Desilva, Binodh ^a   Lee, Jean W ^a  

^a AMGEN INC   (United States)

Author keywords

Fusion protein biotransformation; Immunoaffinity mass spectrometry; In vivo stability of biopharmaceuticals; Ligand binding assay; Peptibodies

Indexed keywords

AMG 195; PEPTIDE ANTIBODY; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; DRUG TRANSFORMATION; ELECTROSPRAY MASS SPECTROMETRY; IMMUNOASSAY; IN VIVO STUDY; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; RAT;

AMINO ACID SEQUENCE; ANIMALS; BIOTRANSFORMATION; IMMUNOASSAY; LIGANDS; MOLECULAR SEQUENCE DATA; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THROMBOPOIETIN;

EID: 78649638244     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9218-9     Document Type: Article

References (15)

1. SR Cummings J San Martin MR McClung ES Siris R Eastell IR Reid, et al. 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 8 756 65 1:CAS:528:DC%2BD1MXhtVWls7nF 10.1056/NEJMoa0809493 19671655
2. S Banerjee H Flores-Rozas 2010 Monoclonal antibodies for targeted therapy in colorectal cancer Cancer Biol Ther. 9 8 563 71 1:CAS:528:DC%2BC3cXhtlKgtrbK 20200482
3. A Klettner J Roider 2009 Treating age-related macular degeneration-interaction of VEGF-antagonists with their target Mini Rev Med Chem 9 9 1127 35 1:CAS:528:DC%2BD1MXhtVWnt7jJ 10.2174/138955709788922665 19689408
4. T Suzuki A Ishii-Watabe M Tada T Kobayashi T Kanayasu-Toyoda T Kawanishi, et al. 2010 Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR J Immunol 184 4 1968 76 1:CAS:528:DC%2BC3cXhsVGlu70%3D 10.4049/jimmunol.0903296 20083659
5. RT Peters SC Low GD Kamphaus JA Dumont JV Amari Q Lu, et al. 2010 Prolonged activity of factor IX as a monomeric Fc fusion protein Blood. 115 10 2057 64 1:CAS:528:DC%2BC3cXhtFensbfJ 10.1182/blood-2009-08-239665 20056791
6. SE Escher U Forssmann A Frimpong-Boateng K Adermann J Vakili H Sticht, et al. 2004 Functional analysis of chemically synthesized derivatives of the human CC chemokine CCL15/HCC-2, a high affinity CCR1 ligand J Pept Res 63 1 36 47 1:CAS:528:DC%2BD2cXht1Wku7c%3D 10.1046/j.1399-3011.2004.00102.x 14984572 (Pubitemid 38174899)
7. M Pernemalm LM Orre J Lengqvist P Wikstrom R Lewensohn J Lehtio 2008 Evaluation of three principally different intact protein prefractionation methods for plasma biomarker discovery J Proteome Res 7 7 2712 22 1:CAS:528:DC%2BD1cXntFWhtbg%3D 10.1021/pr700821k 18549256
8. NL Anderson A Jackson D Smith D Hardie C Borchers TW Pearson 2009 SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device Mol Cell Proteomics 8 5 995 1005 1:CAS:528:DC%2BD1MXmtlygtL8%3D 10.1074/mcp.M800446- MCP200 19196707
9. JE Bandow 2010 Comparison of protein enrichment strategies for proteome analysis of plasma Proteomics. 10 7 1416 25 1:CAS:528:DC%2BC3cXksFGnsb0%3D 10.1002/pmic.200900431 20127685
10. H Wang S Hanash 2009 Electrospray mass spectrometry for quantitative plasma proteome analysis Meth Mol Biol 564 227 42 1:CAS:528: DC%2BC3cXjvVymsQ%3D%3D 10.1007/978-1-60761-157-8-13
11. H Wang S Hanash 2005 Intact-protein based sample preparation strategies for proteome analysis in combination with mass spectrometry Mass Spectrom Rev 24 3 413 26 1:CAS:528:DC%2BD2MXjvFOmu7w%3D 10.1002/mas.20018 15389852 (Pubitemid 40665799)
12. Q Lu X Zheng T McIntosh H Davis JF Nemeth C Pendley, et al. 2009 Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs Anal Chem 81 21 8715 23 1:CAS:528:DC%2BD1MXhtF2ltLjN 10.1021/ac901991x 19788250
13. G Molineux A Newland 2010 Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside Br J Haematol 17 1365 2141
14. RJ Cersosimo 2009 Romiplostim in chronic immune thrombocytopenic purpura Clin Ther 31 9 1887 907 1:CAS:528:DC%2BD1MXhsVCks7rK 10.1016/j.clinthera.2009. 09.013 19843480
15. D Nedelkov 2006 Mass spectrometry-based immunoassays for the next phase of clinical applications Expert Rev Proteomics 3 6 631 40 1:CAS:528: DC%2BD2sXhvFGqtrY%3D 10.1586/14789450.3.6.631 17181477 (Pubitemid 46021199)